These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

954 related articles for article (PubMed ID: 34754128)

  • 1. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.
    Bianchini G; De Angelis C; Licata L; Gianni L
    Nat Rev Clin Oncol; 2022 Feb; 19(2):91-113. PubMed ID: 34754128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic interventions of Triple Negative Breast Cancer.
    Li Z; Qiu Y; Lu W; Jiang Y; Wang J
    J Transl Med; 2018 May; 16(1):147. PubMed ID: 29848327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Therapeutics for Patients with Triple-Negative Breast Cancer.
    Agostinetto E; Eiger D; Punie K; de Azambuja E
    Curr Oncol Rep; 2021 Mar; 23(5):57. PubMed ID: 33763756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
    Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
    Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
    Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets.
    Zambelli A; Sgarra R; De Sanctis R; Agostinetto E; Santoro A; Manfioletti G
    Expert Opin Ther Targets; 2022 Jun; 26(6):557-573. PubMed ID: 35638300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
    Steiner M; Tan AR
    Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the Management of Early-Stage Triple-Negative Breast Cancer.
    Bhardwaj PV; Wang Y; Brunk E; Spanheimer PM; Abdou YG
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast cancer: an impact on classification and treatment approaches.
    Nguyen HM; Paulishak W; Oladejo M; Wood L
    Breast Cancer; 2023 Mar; 30(2):167-186. PubMed ID: 36399321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape.
    Xie X; Lee J; Iwase T; Kai M; Ueno NT
    Expert Opin Ther Targets; 2022 May; 26(5):405-425. PubMed ID: 35574694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The landscape of systemic therapy for early stage triple-negative breast cancer.
    Lu JY; Alvarez Soto A; Anampa JD
    Expert Opin Pharmacother; 2022 Aug; 23(11):1291-1303. PubMed ID: 35818711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Therapies for Triple-Negative Breast Cancer.
    Lyons TG
    Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape.
    Uliano J; Nicolò E; Corvaja C; Taurelli Salimbeni B; Trapani D; Curigliano G
    Expert Rev Clin Pharmacol; 2022 Dec; 15(12):1399-1413. PubMed ID: 36317756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanobiotherapeutic strategies to target immune microenvironment of triple-negative breast cancer.
    Chang Q; Chang L; Li M; Fan L; Bao S; Wang X; Liu L
    Am J Cancer Res; 2022; 12(9):4083-4102. PubMed ID: 36225648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies.
    MacDonald I; Nixon NA; Khan OF
    Curr Oncol; 2022 Jul; 29(7):4768-4778. PubMed ID: 35877238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Mehlich D; Marusiak AA
    Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.
    Khosravi-Shahi P; Cabezón-Gutiérrez L; Custodio-Cabello S
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):32-39. PubMed ID: 28815913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
    Sharma P
    Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.